Panomifene

Drug Profile

Panomifene

Alternative Names: EGIS 5650; GYKl 13504

Latest Information Update: 14 Sep 2010

Price : $50

At a glance

  • Originator IVAX Drug Research Institute
  • Developer Egis Pharmaceuticals; IVAX Drug Research Institute
  • Class Small molecules; Stilbenes
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 26 Oct 1999 IVAX Corporation has acquired the Institute for Drug Research
  • 26 Sep 1997 A clinical study has been added to the pharmacokinetics and adverse events sections
  • 27 May 1997 Phase-II clinical trials for Breast cancer in Hungary (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top